OrbiMed Debuts $222M Israeli Life Sciences Venture Fund

Law360, New York (April 23, 2012, 5:08 PM EDT) -- Investment management firm OrbiMed Advisors LLC on Monday launched a $222 million venture capital fund aimed at beefing up its portfolio with Israeli life sciences companies in a sector fund managers say is coming of age.

The fund, dubbed OrbiMed Israel Partners LP, will target biotechnology, pharmaceutical, medical device and diagnostics companies at varying stages of maturity, from seed stage through growth equity, according to a statement the firm issued Monday.

The fund's first close of $222 million includes an anchor investment from the Israeli government,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.